# Himalaya Early Access Program

> **NCT05345678** · — · APPROVED_FOR_MARKETING · sponsor: **AstraZeneca**

## Conditions studied

- Unresectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT05345678
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2022-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05345678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05345678, "Himalaya Early Access Program". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05345678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*